These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10352136)

  • 1. Ribozymes in gene therapy of HIV-1.
    Macpherson JL; Ely JA; Sun LQ; Symonds GP
    Front Biosci; 1999 Jun; 4():D497-505. PubMed ID: 10352136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of ribozyme gene therapy for the inhibition of HIV replication and its pathogenic sequelae.
    Rigden JE; Ely JA; Macpherson JL; Gerlach WL; Sun LQ; Symonds GP
    Curr Issues Mol Biol; 2000 Apr; 2(2):61-9. PubMed ID: 11471565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HIV ribozymes.
    Sun LQ; Ely JA; Gerlach W; Symonds G
    Mol Biotechnol; 1997 Jun; 7(3):241-51. PubMed ID: 9219238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribozyme therapy for HIV infection.
    Rossi JJ
    Adv Drug Deliv Rev; 2000 Oct; 44(1):71-8. PubMed ID: 11035199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
    Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
    Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of ribozymes to HIV infection.
    Rossi JJ
    Curr Opin Mol Ther; 1999 Jun; 1(3):316-22. PubMed ID: 11713796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV and Ribozymes.
    Scarborough RJ; Gatignol A
    Adv Exp Med Biol; 2015; 848():97-116. PubMed ID: 25757617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy.
    Hampel A
    Prog Nucleic Acid Res Mol Biol; 1998; 58():1-39. PubMed ID: 9308362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.
    Bai J; Banda N; Lee NS; Rossi J; Akkina R
    Mol Ther; 2002 Dec; 6(6):770-82. PubMed ID: 12498773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic applications of ribozymes.
    Kijima H; Ishida H; Ohkawa T; Kashani-Sabet M; Scanlon KJ
    Pharmacol Ther; 1995; 68(2):247-67. PubMed ID: 8719970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
    Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
    Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HIV-1 gp41 expression with hammerhead ribozymes.
    Fedoruk-Wyszomirska A; Szymański M; Głodowicz P; Gabryelska M; Wyszko E; Estrin WJ; Barciszewski J
    Biochem J; 2015 Oct; 471(1):53-66. PubMed ID: 26209679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1.
    Ramezani A; Ma XZ; Nazari R; Joshi S
    Front Biosci; 2002 Feb; 7():a29-36. PubMed ID: 11815297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line.
    Michienzi A; Conti L; Varano B; Prislei S; Gessani S; Bozzoni I
    Hum Gene Ther; 1998 Mar; 9(5):621-8. PubMed ID: 9551610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular susceptibility to ribozymes in a tethered substrate-ribozyme provirus model is not predicted by secondary structures of human immunodeficiency virus type 1 RNAs in vitro.
    Dropulić B; Jeang KT
    Antisense Res Dev; 1994; 4(3):217-21. PubMed ID: 7849493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition.
    Zhou C; Bahner I; Rossi JJ; Kohn DB
    Antisense Nucleic Acid Drug Dev; 1996; 6(1):17-24. PubMed ID: 8783792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic applications of catalytic antisense RNAs (ribozymes).
    Rossi JJ
    Ciba Found Symp; 1997; 209():195-204; discussion 204-6. PubMed ID: 9383577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribozyme gene therapy: applications for molecular medicine.
    Lewin AS; Hauswirth WW
    Trends Mol Med; 2001 May; 7(5):221-8. PubMed ID: 11325634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.
    Akkina R; Banerjea A; Bai J; Anderson J; Li MJ; Rossi J
    Anticancer Res; 2003; 23(3A):1997-2005. PubMed ID: 12894572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.